Topic:

M&A

Latest Headlines

Latest Headlines

Dechra's growth spurt continues with $6M acquisition of Mexican manufacturer

U.K.-based Dechra Pharmaceuticals made a splash last August when it shelled out $56.4 million for a controlling share of Croatian poultry vaccine maker Genara. Now the company is expanding its international footprint to Mexico, acquiring veterinary pharma manufacturer Laboratorios Brovel SA de CV.

Eurofins buys Dutch drug-testing firm to pad its services

Luxembourg testing outfit Eurofins is deepening its work in biopharma, acquiring a specialist in drug testing headquartered in the Netherlands.

GSK chief Witty opens up to spinoff talk, with consumer health an obvious choice

GlaxoSmithKline CEO Andrew Witty may be coming around on a breakup. At the J.P. Morgan Healthcare Conference, Witty said he's open to the idea and pegged his consumer health joint venture with Novartis as a possible option.

Allergan's pipeline doesn't get enough respect, if you ask Pfizer

Pfizer, wending toward a record-setting $160 billion merger with Allergan, said its soon-to-be subsidiary doesn't get the R&D credit it deserves among industry insiders.

Shire CEO thinks he can beat $500M in postmerger cost savings

Shire may have clinched its $32 billion deal to buy Baxalta, but not everyone is breaking out the confetti. Some analysts aren't sold on the tie-up, saying they expected more in the way of savings and still are perplexed by what Baxalta brings to the table.

Depomed isn't anti-takeover, CEO says. It was just anti-Horizon

SAN FRANCISCO-- Let Depomed be clear: it may not have been too keen on Horizon Pharma's buyout offer from last year, but that doesn't mean it's opposed to a takeover.

Smith & Nephew buys cartilage repair product from Piramal

Smith & Nephew sees the arthroscopically delivered cartilage repair solution it's just bought from Montreal, Canada-based Piramal for an undisclosed sum as a first-line treatment. Known as BST-CarGel, it's approved in most of Europe, Australia and Canada.

Now focused on integrating Allergan generics, Teva eyes 'much larger' specialty buy in 2017

SAN FRANCISCO-- After watching months of pharma's M&A wave from the sidelines, Teva finally made a splash this summer with an agreement to pick up Allergan's generics business. And it may not be finished in the dealmaking arena.

Merck buys out IOmet, adding new immuno-oncology tech

Merck has snagged Edinburgh-based IOmet for an undisclosed sum, adding a preclinical pipeline of therapies that target the IDO/TDO pathways that may help spur an immune system attack on cancer.

U.S. med tech venture investment wanes--even as venture-backed M&A holds strong

Venture capital investment in the U.S. jumped to $59 billion last year--almost twice what it was a scant 5 years ago, according to the latest annual healthcare report from Silicon Valley Bank. But medical devices are capturing an ever-shrinking portion of all that largesse for innovation--down to a mere 4% of that VC total for last year or $2.4 billion, which is roughly right where it was in 2014.
'